AURA: Aura Biosciences, Inc. Stock

by  •  • Comments Off on AURA: Aura Biosciences, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 498.02
Enterprise Value ($M) 472.61
Book Value ($M) 174.67
Book Value / Share 3.50
Price / Book 2.85
NCAV ($M) 152.81
NCAV / Share 3.06
Price / NCAV 3.26

Profitability (mra)
Return on Invested Capital (ROIC) -0.43
Return on Assets (ROA) -0.46
Return on Equity (ROE) -0.55

Liquidity (mrq)
Quick Ratio 12.47
Current Ratio 12.47

Balance Sheet (mrq) ($M)
Current Assets 183.48
Assets 205.34
Liabilities 30.67
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
3 days ago 13G/A Lundbeckfond Invest A/S 3.50 -13.26
3 days ago 13G/A Citadel Advisors Llc 0.10
5 days ago 13G/A Adage Capital Management, L.P. 9.84
9 days ago 13G BlackRock, Inc. 6.40 0.00
02-07 13G/A Adage Capital Partners Gp, L.l.c. 8.61 98.10
12-11 13G/A Eventide Asset Management, Llc 11.82 157.74
2023-11-09 13D/A Matrix Capital Management Company, LP 14.10

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-06-14 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2023 OR ☐
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-15 36,051 248,149 14.53
2024-11-14 14,307 88,283 16.21
2024-11-13 13,949 92,011 15.16
2024-11-12 15,689 129,433 12.12
2024-11-11 17,727 126,556 14.01

(click for more detail)

Similar Companies
ATAI – Atai Life Sciences N.V. ATXS – Astria Therapeutics, Inc.
AUPH – Aurinia Pharmaceuticals Inc. AVBP – ArriVent BioPharma, Inc.
AVDL – Avadel Pharmaceuticals plc


Financial data and stock pages provided by
Fintel.io